Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study

about

Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study

Item

http://www.wikidata.org/entity/Q57162415

description

im September 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована у вересні 2018

@uk

name

Venetoclax, bendamustine, and ...... a phase Ib dose-finding study

@en

Venetoclax, bendamustine, and ...... a phase Ib dose-finding study

@nl

type

Item

label

Venetoclax, bendamustine, and ...... a phase Ib dose-finding study

@en

Venetoclax, bendamustine, and ...... a phase Ib dose-finding study

@nl

prefLabel

Venetoclax, bendamustine, and ...... a phase Ib dose-finding study

@en

Venetoclax, bendamustine, and ...... a phase Ib dose-finding study

@nl

P1476

Venetoclax, bendamustine, and ...... a phase Ib dose-finding study

@en

P2093

A H Salem

http://www.w3.org/2001/XMLSchema#string

A M Petrich

http://www.w3.org/2001/XMLSchema#string

C Nolan

http://www.w3.org/2001/XMLSchema#string

C R Flowers

http://www.w3.org/2001/XMLSchema#string

D Wang

http://www.w3.org/2001/XMLSchema#string

E Reid

http://www.w3.org/2001/XMLSchema#string

J A Ross

http://www.w3.org/2001/XMLSchema#string

J Cordero

http://www.w3.org/2001/XMLSchema#string

L J Nastoupil

http://www.w3.org/2001/XMLSchema#string

L J Swinnen

http://www.w3.org/2001/XMLSchema#string

P2860

The Bcl-2 apoptotic switch in cancer development and therapy

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Cell death: critical control points

Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma.

Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma.

Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma.

Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma.

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.

Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

Bcl-2-family proteins and hematologic malignancies: history and future prospects.

P304

1932-1938

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDY256

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Suresh K Agarwal

P577

2018-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30060083

http://www.w3.org/2001/XMLSchema#string

P921

hematology

P932

6158762

http://www.w3.org/2001/XMLSchema#string